Tirzepatide 10mg
Dual-Action Weight Loss
View Certificate of AnalysisThird-party verified · 99.65% purity · 10.34 mg contentHPLC-UV by Testides (Toronto) · Lot TIRZ10-0626-01 · View COA →Compound Overview
✓ Lab results are in. This batch independently verified at 99.65% purity (HPLC-UV 214nm) by Testides — lot TIRZ10-0626-01, 10.34 mg, reported July 2, 2026. View the full certificate →
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide developed by Eli Lilly — the first dual-incretin agonist to receive regulatory approval (Mounjaro®, Zepbound®). This 10mg vial provides lyophilized tirzepatide at 99.65% verified purity for laboratory studies investigating dual-pathway incretin signaling.
Lab results: View current batch COA (Testides)
Compare in our Semaglutide vs Tirzepatide vs Retatrutide Comparison Guide.
Specifications
| Compound | Tirzepatide |
| Compound class | Dual GIP / GLP-1 receptor agonist peptide |
| Vial contents | 10 mg lyophilized powder (lot assayed at 10.34 mg) |
| Current lot | TIRZ10-0626-01 |
| Verified purity | 99.65% (HPLC-UV, 214nm) |
| Testing laboratory | Testides, Toronto (ISO 17025-aligned) |
| Report date | July 2, 2026 — view certificate |
| Compatible solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Storage | Lyophilized: -20°C long-term, 2-8°C short-term |
| Research applications | Dual-incretin signalling, GIP and GLP-1 receptor pathways, glycaemic regulation, appetite and body composition research |
| Related compounds | Semaglutide (single agonist), Retatrutide (triple agonist) |
| Ships from | British Columbia, Canada |
| Intended use | In-vitro laboratory research only |
Research Context & Mechanism+
Tirzepatide simultaneously activates both GIP and GLP-1 receptors. SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID: 35658024) demonstrated substantial body weight reduction. SURPASS-2 (Frías et al., NEJM 2021, PMID: 34170647) showed superiority over semaglutide in glycemic control — a direct head-to-head comparison highly relevant for incretin pathway research.
Tirzepatide sits between semaglutide (single GLP-1 agonist) and retatrutide (triple agonist) in the receptor-activation spectrum. Read the full comparison →
Purity & Third-Party Testing+
Independently tested by Testides (Toronto) by HPLC-UV for purity and mass spectrometry for identity. Current lot TIRZ10-0626-01: 99.65% purity (HPLC-UV 214nm), 10.34 mg, reported July 2, 2026. View the certificate of analysis →
Storage & Handling+
Lyophilized: -20°C long-term, 2-8°C short-term.
Shipping & Delivery+
Ships from BC. Tracked Canada-wide. 48-hour processing. Shipping policy →
Returns & Refunds+
Contact info@thepeptide.ca within 48 hours for damaged orders. Sealed vials eligible for exchange within 14 days. Refund policy →
For laboratory and research use only. Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada.
- Sealed vial: −20°C, 24+ months.
- Protect from light and heat.
- Keep in original packaging until use in the laboratory.
- CAS: 2023788-19-2
- Molecular weight: 4,813.45 g/mol
- Class: Dual GIP / GLP-1 receptor agonist
- Purity: ≥99% (HPLC)
Not for human or animal use. We do not publish preparation, dilution or administration guidance of any kind.
By purchasing, you confirm research intent and accept full responsibility for compliance.
Mix any research peptides 10 mg or larger — the discount counts your whole order, not one product.
YOU MAY ALSO LIKE
SHOP ALL
Frequently Bought Together
Laboratory supplies commonly ordered alongside research compounds.
Bacteriostatic Water 10mL — Sterile Multi-Use Laboratory Water with 0.9% Benzyl Alcohol
Essential Reconstitution Supply
STARTING AT ▸ $22.00
Insulin Syringes 10-Pack — 1mL, 29G × ½" Sterile Single-Use Laboratory Syringes
Sterile. Ultra-fine. Individually wra...
Why ThePeptide
Most research peptide sellers ask you to take their word for it. We publish the receipts.
